Project Grant R43CA310377
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $405K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Ramon, CA 94582, USA
Similar Awards
- The National Cancer Institute awarded Simplusdx, Inc. $532,105 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a point-of-care screening test for hepatocellular carcinoma. Simplusdx will finalize development and clinically translate a point-of-care surveillance test for HCC using the D4 immunoassay platform, a nonfouling poly(oligoethylene glycol methyl ether methacrylate) brush that enables multiplexed, high-sensitivity...
- The National Cancer Institute awarded The Johns Hopkins University $645,435 on September 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a multimodal blood-based classifier for early hepatocellular carcinoma (HCC) detection. The research integrates genome-wide methods—fragmentomics (DELFI), repeat landscapes (ARTEMIS), methylomics, mutational signatures (GEMINI), and plasma proteomics—into a single machine learning classifier to improve HCC...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...
- The National Cancer Institute awarded the University of Houston System $656,935 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop nanophotonic single exosome liquid biopsy technology for hepatocellular carcinoma screening and diagnosis. The project addresses limitations in current hepatocellular carcinoma surveillance methods, which rely on ultrasound and serum alfa-fetoprotein measurements that lack sensitivity and specificity for early...
- The National Cancer Institute awarded University of Connecticut Health Center $414,585 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform for detecting cell-free DNA mutations in blood samples to enable noninvasive, early detection of lung cancer. The project will advance a PCR-based PEAM-SEQ V1.0 assay into a simplified PEAM-SEQ V2.0 assay by combining...
- The National Cancer Institute awarded Massachusetts Eye and Ear Infirmary $642,406 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, for research on blood-based early detection of viral precancers. The project, titled "Blood-Based Early Detection of Viral Precancers," develops liquid biopsy screening methods to detect cancers at their inception by targeting viral cell-free DNA. Current liquid biopsy approaches that detect mutated or methylated...
- The National Cancer Institute awarded The University of Chicago $692,063 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance early colorectal cancer diagnosis and risk stratification using DNA methylation markers. The funded work develops blood-based biomarkers to detect colorectal cancer and advanced adenomas through cell-free DNA analysis, addressing the gap in sensitivity of existing tools such as MSEPT9, Cologuard, and Shield. The research...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...
- The National Cancer Institute awarded Intus Biosciences LLC $404,338 on August 19, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a non-invasive, bacterial biomarker-based screening assay for early-onset colorectal cancer in patients younger than 50 and precancerous lesions. The recipient will build the assay on Intus Biosciences' Titan-1 platform, a high-throughput strain-level bacterial profiling technology currently available as a laboratory developed...